Dosing time dependent in vitro pharmacodynamics of Everolimus despite a defective circadian clock

Everolimus (EV), a rapamycin analogue mTOR inhibitor, is used in the clinic to treat Estrogen positive (ER(+)) breast cancer in order to avoid the resistance to hormonotherapy. Here, we investigated whether EV efficacy varied according to administration timing by using the ER(+) breast cancer cell l...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Cell Cycle
Main Authors: Zhang, Yuan, Giacchetti, Sylvie, Parouchev, Alexandre, Hadadi, Eva, Li, Xiaomei, Dallmann, Robert, Xandri-Monje, Helena, Portier, Lucie, Adam, René, Lévi, Françis, Dulong, Sandrine, Chang, Yunhua
Formato: Artigo
Idioma:Inglês
Publicado em: Taylor & Francis 2018
Assuntos:
Reports
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC5815427/
https://ncbi.nlm.nih.gov/pubmed/29099263
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/15384101.2017.1387695
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados